Cargando…

It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials

The Good Clinical Practices (GCP) codes of the WHO and the International Conference of Harmonization set international standards for clinical research. But critics argue that they were written without consideration for the challenges faced in low and middle income countries (LMICs). Based on our fie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravinetto, Raffaella, Tinto, Halidou, Diro, Ermias, Okebe, Joseph, Mahendradhata, Yodi, Rijal, Suman, Gotuzzo, Eduardo, Lutumba, Pascal, Nahum, Alain, De Nys, Katelijne, Casteels, Minne, Boelaert, Marleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321366/
https://www.ncbi.nlm.nih.gov/pubmed/28588969
http://dx.doi.org/10.1136/bmjgh-2016-000122
_version_ 1782509682263326720
author Ravinetto, Raffaella
Tinto, Halidou
Diro, Ermias
Okebe, Joseph
Mahendradhata, Yodi
Rijal, Suman
Gotuzzo, Eduardo
Lutumba, Pascal
Nahum, Alain
De Nys, Katelijne
Casteels, Minne
Boelaert, Marleen
author_facet Ravinetto, Raffaella
Tinto, Halidou
Diro, Ermias
Okebe, Joseph
Mahendradhata, Yodi
Rijal, Suman
Gotuzzo, Eduardo
Lutumba, Pascal
Nahum, Alain
De Nys, Katelijne
Casteels, Minne
Boelaert, Marleen
author_sort Ravinetto, Raffaella
collection PubMed
description The Good Clinical Practices (GCP) codes of the WHO and the International Conference of Harmonization set international standards for clinical research. But critics argue that they were written without consideration for the challenges faced in low and middle income countries (LMICs). Based on our field experience in LMICs, we developed a non-exhaustive set of recommendations for the improvement of GCP. These cover 3 domains: ethical, legal and operational, and 8 specific issues: the double ethical review of ‘externally sponsored’ trials; the informed consent procedure in minors and in illiterate people; post-trial access to newly-developed products for the trial communities; the role of communities as key research actors; the definition of sponsor; and the guidance for contractual agreements, laboratory quality management systems, and quality assurance of investigational medicinal products. Issues not covered in our analysis include among others biobanking, standard of care, and study designs. The international GCP codes de facto guide national legislators and funding agencies, so the current shortcomings may weaken the regulatory oversight of international research. In addition, activities neglected by GCP are less likely to be implemented or funded. If GCP are meant to serve the interests of global society, a comprehensive revision is needed. The revised guidelines should be strongly rooted in ethics, sensitive to different sociocultural perspectives, and allow consideration for trial-specific and context-specific challenges. This can be only achieved if all stakeholders, including researchers, sponsors, regulators, ethical reviewers and patients' representatives from LMICs, as well as non-commercial researchers and sponsors from affluent countries, are transparently involved in the revision process. We hope that our limited analysis would foster advocacy for a broad and inclusive revision of the international GCP codes, to make them at the same time ‘global’, ‘context centred’ and ‘patient centred’.
format Online
Article
Text
id pubmed-5321366
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53213662017-06-06 It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials Ravinetto, Raffaella Tinto, Halidou Diro, Ermias Okebe, Joseph Mahendradhata, Yodi Rijal, Suman Gotuzzo, Eduardo Lutumba, Pascal Nahum, Alain De Nys, Katelijne Casteels, Minne Boelaert, Marleen BMJ Glob Health Analysis The Good Clinical Practices (GCP) codes of the WHO and the International Conference of Harmonization set international standards for clinical research. But critics argue that they were written without consideration for the challenges faced in low and middle income countries (LMICs). Based on our field experience in LMICs, we developed a non-exhaustive set of recommendations for the improvement of GCP. These cover 3 domains: ethical, legal and operational, and 8 specific issues: the double ethical review of ‘externally sponsored’ trials; the informed consent procedure in minors and in illiterate people; post-trial access to newly-developed products for the trial communities; the role of communities as key research actors; the definition of sponsor; and the guidance for contractual agreements, laboratory quality management systems, and quality assurance of investigational medicinal products. Issues not covered in our analysis include among others biobanking, standard of care, and study designs. The international GCP codes de facto guide national legislators and funding agencies, so the current shortcomings may weaken the regulatory oversight of international research. In addition, activities neglected by GCP are less likely to be implemented or funded. If GCP are meant to serve the interests of global society, a comprehensive revision is needed. The revised guidelines should be strongly rooted in ethics, sensitive to different sociocultural perspectives, and allow consideration for trial-specific and context-specific challenges. This can be only achieved if all stakeholders, including researchers, sponsors, regulators, ethical reviewers and patients' representatives from LMICs, as well as non-commercial researchers and sponsors from affluent countries, are transparently involved in the revision process. We hope that our limited analysis would foster advocacy for a broad and inclusive revision of the international GCP codes, to make them at the same time ‘global’, ‘context centred’ and ‘patient centred’. BMJ Publishing Group 2016-11-16 /pmc/articles/PMC5321366/ /pubmed/28588969 http://dx.doi.org/10.1136/bmjgh-2016-000122 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Analysis
Ravinetto, Raffaella
Tinto, Halidou
Diro, Ermias
Okebe, Joseph
Mahendradhata, Yodi
Rijal, Suman
Gotuzzo, Eduardo
Lutumba, Pascal
Nahum, Alain
De Nys, Katelijne
Casteels, Minne
Boelaert, Marleen
It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials
title It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials
title_full It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials
title_fullStr It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials
title_full_unstemmed It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials
title_short It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials
title_sort it is time to revise the international good clinical practices guidelines: recommendations from non-commercial north–south collaborative trials
topic Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321366/
https://www.ncbi.nlm.nih.gov/pubmed/28588969
http://dx.doi.org/10.1136/bmjgh-2016-000122
work_keys_str_mv AT ravinettoraffaella itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT tintohalidou itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT diroermias itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT okebejoseph itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT mahendradhatayodi itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT rijalsuman itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT gotuzzoeduardo itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT lutumbapascal itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT nahumalain itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT denyskatelijne itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT casteelsminne itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials
AT boelaertmarleen itistimetorevisetheinternationalgoodclinicalpracticesguidelinesrecommendationsfromnoncommercialnorthsouthcollaborativetrials